The CTR9 antibody targets the CTR9 protein, a key subunit of the Polymerase-Associated Factor 1 (PAF1) complex, which is evolutionarily conserved and plays multifaceted roles in transcriptional regulation, histone modification, and mRNA processing. The PAF1 complex, comprising CTR9. LEO1. PAF1. CDC73. and RTF1. associates with RNA polymerase II, influencing elongation and epigenetic marks like H2B ubiquitination and H3K4 methylation. CTR9 is critical for maintaining complex stability and recruiting additional partners.
Research highlights CTR9's involvement in embryonic development, stem cell pluripotency, and oncogenesis. It regulates Wnt/β-catenin signaling and MYC expression, linking it to cancers such as colorectal carcinoma and breast cancer. Dysregulation of CTR9 correlates with tumor progression, metastasis, and poor prognosis, suggesting its dual role as an oncogene or tumor suppressor depending on context.
CTR9 antibodies are essential tools for studying these mechanisms, enabling detection of protein _expression (via Western blot, immunofluorescence, or immunohistochemistry), mapping interactions (co-immunoprecipitation), and exploring clinical associations. Recent studies also probe CTR9's potential as a therapeutic target or biomarker. However, functional heterogeneity across tissues and diseases necessitates careful experimental validation to ensure antibody specificity and relevance to particular biological or pathological models.